Breaking News, Collaborations & Alliances

Ionis, Roche Partner on RNA-targeted Programs for AD and HD

Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by Ionis.

Ionis Pharmaceuticals, Inc. entered an agreement with Roche for two early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer’s disease (AD) and Huntington’s disease (HD). Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and commercialization of the medicines if they receive regulatory approval. The companies will leverage Ionis’ discovery expertise for medicines that target the root ca...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters